Can a new injection tame prostate cancer by cutting testosterone?

NCT ID NCT06490328

Completed Disease control Sponsor: Dongkook Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase 3 trial is testing an investigational drug called DKF-MA102 (leuprorelin acetate) in men with advanced prostate cancer. The goal is to see if two injections, given 12 weeks apart, can safely lower testosterone levels to a target range, which may help control the cancer. The study will also monitor changes in PSA and luteinizing hormone levels over 24 weeks. Participants are adult men with confirmed prostate cancer and elevated testosterone levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: leuprorelin acetate (DKF-MA102), a hormone therapy given as an injection
What this could lead to: If successful, this could offer a new treatment option to control advanced prostate cancer by suppressing testosterone, potentially slowing disease progression.
What could go wrong: This is an early-stage, single-group study without a comparison group, so results may not be definitive. Hormone therapy can cause side effects like hot flashes, fatigue, and loss of libido.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE CANCER

Contacts and locations

Locations

Asan Medical Center

Seoul, South Korea
Ewha Womans University mokdong Hospital

Seoul, South Korea
Gangnam Severance Hospital, Yonsei University College of Medicine

Seoul, South Korea
National Cancer Center

Gyeonggi-do, South Korea
Samsung Medical Center

Seoul, South Korea
Seoul National University Bundang Hospital

Gyeonggi-do, South Korea
Seoul National University Hospital

Seoul, South Korea
Seoul Saint. Mary's Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.